Availability and prices of medications used during COVID-19 pandemic

Main Article Content

Khansaa A.Ibrahim Albaroodi https://orcid.org/0000-0003-4523-150X

Keywords

availability, prices, medications, high price, local

Abstract

Objectives: The present COVID-19 pandemic has impacted all of us, but the pandemic’s impact and repercussions are perceived differently by individuals and governments. Locking down had an impact on pharmaceutical manufacturing, supply, and distribution, causing a medicine shortage. This study aimed to assess drugs used frequently during the pandemic in Iraq their availability and prices and determine how medications are affordable for patients. Study design: This was a pilot study. Methods: This study enrolled 30 pharmacies from rural and urban areas located in Babil governorate, Iraq; from 1 January until 1 March 2021. Results: According to the results, there was a difference between expensive and inexpensive medicines. Medication availability shows that many COVID-19 used medications had no local production like ipratropium, budesonide, Enoxaparin, remdesivir, and others. Levofloxacin vial 500 mg, cost more than 9000 Iraqi dinars, which is more than one day of Iraqi wage (1 day of salary = 8333 Iraqi Dinar; levofloxacin is normally given for seven days, so the total cost will be 583333 Iraqi Dinar for the entire course) that’s rather than other medications and for one family member. Local production prices are high in comparison to imported ones, as in (levofloxacin and Favipiravir). Many medications had increased their prices after the pandemic due to demand, availability and exchange rate. Conclusion: The Iraqi government has to provide medications for the Iraqi people in public hospitals and clinics so that patients do not need to go to private ones. Medications prices have to be controlled uninformed by the government.

Abstract 1121 | PDF Downloads 260

References

1. Guarner J. Three emerging coronaviruses in two decades: the story of SARS, MERS, and now COVID-19. Oxford University Press US. 2020;420-421.
2. world Health Organisation. Novel Coronavirus – China. https://www.who.int/csr/don/12-january-2020-novel-coronaviruschina/ en/: WHO; 2020 8/June. Available from: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.
3. Centers for disease control and prevention. COVID-19. CDC; 2021 16-June. Available from: https://www.cdc.gov/ coronavirus/2019-ncov/symptoms-testing/symptoms.html.
4. World Health Organisation. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-oncovid- 19---11-march-2020: WHO; 2020 8/June. Available from: https://www.who.int/director-general/speeches/detail/whodirector- general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
5. European Medicines Agency. Availability of medicines during COVID-19 pandemic European Medicines Agency; 2021 11-April. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-diseasecovid- 19/availability-medicines-during-covid-19-pandemic.
6. Haque M, Kumar S, Charan J, et al. Utilisation, availability and price changes of medicines and protection equipment for COVID-19 among selected regions in India: Findings and implications. Frontiers in pharmacology. 2021;11:582154.. https:// doi.org/10.3389/fphar.2020.582154
7. Reyes MV. STUDENT ESSAY The Disproportional Impact of COVID-19 on African Americans. http://www.ncbi.nlm.nih.gov/pmc/ articles/pmc7762908/
8. WOrld Health Organisation. COVID-19 dynamic infographic dashboard Iraq 2020-2022. WHO; 2022 7-June. Available from: https://app.powerbi.com/view?r=eyJrIjoiNjljMDhiYmItZTlhMS00MDlhLTg3MjItMDNmM2FhNzE5NmM4IiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9
9. Weekly epidemiological update on COVID-19 - 1 June 2021, (42, 2021).
10. Organization WH. WHO medicines strategy 2004-2007: countries at the core. 2004. World Health Organization.
11. Treasury HMs, Revenue I. Increasing access to essential medicines in the developing world: UK Government policy and plans.
12. Organization WH. The world medicines situation. 2004. World Health Organization.
13. McIntyre D, Thiede M, Dahlgren G, et al. What are the economic consequences for households of illness and of paying for health care in low-and middle-income country contexts? Social science & medicine. 2006;62(4):858-865. https://doi.org/10.1016/j. socscimed.2005.07.001
14. Bale H. Consumption and trade in off-patented medicines. WHO Commission for Macroeconomics and Health Working Paper, February. 2001.
15. Organization WH. WHO guideline on country pharmaceutical pricing policies. World Health Organization; 2015. ISBN: 9241549033.
16. Wagner JL, McCarthy E. International differences in drug prices. Annu Rev Public Health. 2004;25:475-495. https://doi. org/10.1146/annurev.publhealth.25.101802.123042
17. Kasapçopur Ö. A Big Problem and debate in COVID-19 pandemics: equitable and effective access of the COVID-19 vaccines and waiver of intellectual property. Turkish Archives of Pediatrics. 2021;56(4):283. https://doi.org/10.5152/ turkarchpediatr.2021.180621
18. Myhr K. Comparing prices of essential drugs between four East African countries and with international prices. Amsterdam: Health Action International. 2000;22:158-165.
19. Bala K, Sagoo K. Patents and prices. HAI news. 2000;112:1-11.
20. Gencarelli D. Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? 2002;1(775):1- 19. http://www.ncbi.nlm.nih.gov/books/nbk561162/
21. Srivastava D, McGuire A. Analysis of prices paid by low-income countries-how price sensitive is government demand for medicines? BMC Public Health. 2014;14(1):1-12. https://doi.org/10.1186/1471-2458-14-767
22. Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The lancet. 2009;373(9659):240-249. https://doi.org/10.1016/s0140-6736(08)61762-6
23. Saeed A, Saeed H, Saleem Z, et al. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology. PloS one. 2019;14(4):e0216122. https://doi.org/10.1371/ journal.pone.0216122
24. The World Bank. GDP per capita (current US$). The World Bank; 2022 14-May. Available from: https://data.worldbank.org/ indicator/NY.GDP.PCAP.CD.
25. International Organization for Standardization. Country Codes Collection. 2023 11-June. Available from: https://www.iso.org/ obp/ui/#search/code/.
26. Haque M, Islam S, Iqbal S, et al. Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. Bangladesh Journal ofMedical Science. 2020:36-S 50.
27. Aljadeed R, AlRuthia Y, Balkhi B, et al. The impact of COVID-19 on essential medicines and personal protective equipment availability and prices in Saudi Arabia. Healthcare; 2021. Multidisciplinary Digital Publishing Institute. 2021;9(3):290. https:// doi.org/10.3390/healthcare9030290
28. Ayati N, Saiyarsarai P, Nikfar S. Short and long term impacts of COVID-19 on the pharmaceutical sector. Daru. 2020;28(2):799- 805. https://doi.org/10.1007/s40199-020-00358-5
29. Cohen J, Neumann P, Ollendorf D. Valuing and pricing remdesivir: should drug makers get paid for helping us get back to work. Health Affairs Blog https://www healthaffairs https://doi.org/101377/hblog20200518. 2020;966027
30. Institute for Clinical and Economic Review. Alternative pricing models for remdesivir and other potential treatments for COVID-19. Institute for Clinical and Economic Review; 2020 5-June. Available from: https://icer.org/news-insights/pressreleases/ alternative_pricing_models_for_remdesivir/.
31. Akour A, Elayeh E, Tubeileh R, et al. Role of community pharmacists in medication management during COVID-19 lockdown. Pathogens and Global Health. 2021 2021/04/03;115(3):168-177. https://doi.org/10.1080/20477724.2021.1884806.
32. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention Global Initiative for Asthma; 2022 5-June. Available from: https://ginasthma.org/wp-content/uploads/2022/05/GINA-Main-Report-2022-FINAL-22-05-03-WMS.pdf
33. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal. 2003;21(1):74-81. https://doi.org/10.1183/09031936.03.00031402
34. Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respiratory investigation. 2020;58(3):155-168. https://doi.org/10.1016/j.resinv.2019.12.005
35. Heinen N, Meister TL, Klöhn M, et al. Antiviral Effect of Budesonide against SARS-CoV-2. Viruses. 2021;13(7):1411. https://doi. org/10.3390/v13071411.
36. National Institutes for Health and Care Excelence. COVID-19 rapid guideline: critical care in adults. NICE; 2020 5-June. Available from: https://www.nice.org.uk/guidance/ng159.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>